SSA
ABEO icon

Schonfeld Strategic Advisors’s Abeona Therapeutics ABEO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-65,011
Closed -$309K – 1984
2025
Q1 		$309K Buy
65,011
+3,745
+6% +$20.4K ﹤0.01% 1771
2024
Q4 		$341K Buy
+61,266
New +$377K ﹤0.01% 1565
2023
Q4 		– Sell
-153,930
Closed -$648K – 1829
2023
Q3 		$648K Buy
+153,930
New +$582K 0.01% 1142
2020
Q1 		– Sell
-58,268
Closed -$4.76M – 1095
2019
Q4 		$4.76M Buy
+58,268
New +$4.11M 0.12% 203
2019
Q3 		– Sell
-14,756
Closed -$1.76M – 992
2019
Q2 		$1.76M Buy
14,756
+6,000
+69% +$1.01M 0.06% 312
2019
Q1 		$1.61M Buy
8,756
+232
+3% +$41.5K 0.06% 393
2018
Q4 		$1.52M Buy
+8,524
New +$1.86M 0.06% 376

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Schonfeld Strategic Advisors's ABEO Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2025, closing a stake of 65,011 shares — an estimated $309K sold.

Schonfeld Strategic Advisors first reported a position in ABEO in Q4 2018 and held it in 7 quarters. The position peaked at $4.76M in Q4 2019. 95 funds tracked by Wall St. Rank hold ABEO as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Abeona Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 65,011 Abeona Therapeutics shares in Q2 2025, an estimated $309K.
  • Schonfeld Strategic Advisors first reported a position in Abeona Therapeutics in Q4 2018 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Abeona Therapeutics position peaked at $4.76M in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.